CHA₂DS₂-VA vs CHA₂DS₂-VASc: What the 2024 ESC AF Guideline Changed

For more than a decade, CHA₂DS₂-VASc was the default stroke risk score in atrial fibrillation (AF). The 2024 European Society of Cardiology (ESC) guideline replaced it with CHA₂DS₂-VA: the same score without the "Sc" (sex category) point [1]. The edit is small on paper, but it changes who sits on which side of the anticoagulation threshold, and it shows up in exams and on ward rounds alike.

Here is what changed, how to score it, and where the score stops being useful.

The short version

• The 2024 ESC guideline uses CHA₂DS₂-VA, which has no sex criterion, to estimate thromboembolic risk in AF [1].
• Score ≥2: oral anticoagulation (OAC) is recommended. Score 1: OAC should be considered, as a shared decision [1, 2].
• Hypertrophic cardiomyopathy and cardiac amyloidosis: OAC is recommended regardless of score [2].
• Bleeding risk scores should not be used to withhold or stop OAC. The emphasis is on finding and fixing modifiable bleeding risk factors [1, 3].
• DOACs are preferred over vitamin K antagonists (VKAs), except with mechanical heart valves or moderate-to-severe mitral stenosis [1, 2].

Try it with the CHA₂DS₂-VA calculator.

Scoring CHA₂DS₂-VA

Definitions follow Table 10 of the ESC guideline [1]:

The maximum is now 8 points instead of 9.

Why remove sex?

CHA₂DS₂-VASc was derived in 2010 from the Euro Heart Survey and gave one point for female sex [7]. The ESC task force gives three reasons for dropping it [1]:

1. Female sex behaves as an age-dependent risk modifier, not a risk factor in its own right. Without other risk factors it adds little or nothing. That is why the old score needed sex-specific thresholds: a woman with a score of 1 (from sex alone) counted as low risk, like a man with 0.
2. Including sex made the score harder to use for clinicians and patients.
3. It left people out, including those who are non-binary, transgender or receiving sex hormone therapy.

With CHA₂DS₂-VA the same thresholds apply to everyone. For exam purposes: a score of 1 always means "consider OAC", whatever the patient's sex.

From score to decision

The guideline wording is that OAC is recommended at a CHA₂DS₂-VA score of 2 or more and should be considered at a score of 1 [1, 2]. Guideline summaries report these as class I and class IIa recommendations respectively [2, 4]. At 0 the risk is low enough that OAC is generally not indicated.

The guideline also allows thromboembolic risk to be assessed with locally validated tools and additional risk factors, not the score alone [2]. CHA₂DS₂-VA informs the decision; it does not make it.

Conditions that override the score

In AF with hypertrophic cardiomyopathy or cardiac amyloidosis, OAC is recommended regardless of the CHA₂DS₂-VA score [2]. The score underestimates risk in both.

Risk changes over time

Stroke risk rises with age and with new diagnoses such as hypertension, diabetes or heart failure. The guideline asks for dynamic reassessment as part of the AF-CARE pathway [1]. A patient who scores 0 today may score 2 a few years later.

Where the score fits: AF-CARE

The 2024 guideline organises AF management around AF-CARE [2]:

• C: Comorbidity and risk factor management
• A: Avoid stroke and thromboembolism
• R: Reduce symptoms by rate and rhythm control
• E: Evaluation and dynamic reassessment

CHA₂DS₂-VA belongs to "A". Comorbidity management comes first on purpose, since blood pressure, weight, alcohol, sleep apnoea and diabetes all drive AF itself as well as bleeding risk.

What happened to HAS-BLED?

HAS-BLED was developed in 2010 from the Euro Heart Survey to estimate one-year major bleeding risk on anticoagulation [5], and earlier ESC guidelines featured it prominently.

The 2024 guideline takes a different line [1, 3]:

• The task force does not recommend a specific bleeding risk score, citing uncertainty about their accuracy.
• Bleeding risk scores should not be used to decide against starting OAC or to stop it. Estimated bleeding risk is rarely a reason to withhold OAC from an otherwise eligible patient.
• Clinicians should instead identify and treat modifiable bleeding risk factors: uncontrolled hypertension, concomitant antiplatelets or NSAIDs, excess alcohol, anaemia and labile INR on a VKA.

Some summaries still describe HAS-BLED as a way to structure that assessment and flag high-risk patients for closer follow-up [2]. Either way, a high HAS-BLED score is a prompt to fix risk factors and review more often. It is not a contraindication to OAC.

Structured checklist: HAS-BLED calculator.

DOAC or VKA?

DOACs (apixaban, dabigatran, edoxaban, rivaroxaban) are preferred over VKAs [2]. Compared with warfarin they are at least non-inferior for efficacy and roughly halve intracranial haemorrhage [3].

Exceptions: with mechanical heart valves or moderate-to-severe mitral stenosis, VKAs remain the only option [1].

Two practical points from the guideline:

• Avoid inappropriate dose reduction. Start DOACs at the full dose tested in the phase 3 trials and reduce only when the drug-specific criteria are met. Off-label underdosing increases stroke risk without lowering bleeding risk [2, 3].
• Use the right kidney function estimate. The EHRA practical guide recommends Cockcroft-Gault creatinine clearance for DOAC dosing, because that is what the pivotal trials used [6]. See Interpreting eGFR and the Cockcroft-Gault calculator.

Antiplatelet therapy alone is not recommended for stroke prevention in AF. Combining it with OAC is reserved for selected situations such as an acute coronary syndrome [2, 3].

Worked examples

These cases are for practising the scoring only, not treatment advice for real patients.

The third row is the heart of the change. Under the old score the 68-year-old woman scored 2. Under the new one she scores 1, the same as a man of the same age, and the guideline leaves room for a shared decision.

Common mistakes

• Mixing scores and thresholds: calculating CHA₂DS₂-VASc but applying CHA₂DS₂-VA thresholds, or the reverse.
• Reading "vascular disease" too narrowly. Table 10 includes significant CAD on imaging and complex aortic plaque, not just prior MI and PAD [1].
• Counting heart failure only with reduced EF. "C" applies to symptoms and signs of HF irrespective of LVEF [1].
• Using HAS-BLED as a veto. See above.
• Scoring once and never again. Risk changes with age and comorbidity.

Not everyone has switched

The ESC is not the only voice. A commentary on the guideline notes that US guidance has kept HAS-BLED [4], and many cohort studies were analysed with CHA₂DS₂-VASc. When you read a paper or a non-European guideline, check which score it uses before comparing thresholds.

Bottom line

CHA₂DS₂-VA simplifies stroke risk assessment in AF: one set of thresholds for everyone and fewer special cases. The main practical shift concerns women with few risk factors. Alongside it, the guideline moves bleeding assessment away from scores and towards treatable risk factors. For exams, know the table, the thresholds (≥2 recommend, 1 consider) and the exceptions (HCM, amyloidosis, mechanical valves, mitral stenosis).

If you want to check a detail of the guideline quickly, Medelix answers with citations so you can open and verify the original source.

Sources

1. Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3314–3414. doi:10.1093/eurheartj/ehae176
2. American College of Cardiology. 2024 ESC Guidelines for Management of Atrial Fibrillation: Key Points. 2024. acc.org
3. Wade T. Linking to the 2024 ESC Guidelines on Atrial Fibrillation: "6. [A] Avoid stroke and thromboembolism" (annotated guideline excerpts). tomwademd.net
4. 2024 European Society of Cardiology Atrial Fibrillation Guidelines: Moving Goalposts? European Cardiology Review. ecrjournal.com
5. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093–1100. doi:10.1378/chest.10-0134
6. Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021;23(10):1612–1676. PMC11636576
7. Lip GYH, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest. 2010;137(2):263–272. doi:10.1378/chest.09-1584